DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a research note issued to investors on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Down 1.9 %

Shares of DRRX stock opened at $0.95 on Friday. The firm’s 50 day moving average is $1.07 and its 200 day moving average is $1.30. The stock has a market capitalization of $29.49 million, a P/E ratio of -1.56 and a beta of 1.01. DURECT has a 12 month low of $0.51 and a 12 month high of $1.88.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Richmond Brothers Inc. boosted its position in DURECT by 39.5% during the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after buying an additional 303,670 shares during the period. Geode Capital Management LLC raised its stake in shares of DURECT by 4.8% during the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in shares of DURECT by 41.3% during the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 6,300 shares during the period. Institutional investors own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.